FILTER
FILTERED INTERVIEW RESULTS
Robert E. Landry
EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.
Donna LaVoie
PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
LaVoie Health Science explains how the communication requirements for Biotech companies have evolved significantly.
Jeff Reingold
COO, CONTRACT PHARMACAL CORP
Contract Pharmacal Corp explains how it is intends to maintain its organic growth.
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios explains its developments in Critical Fluid Inactivation, cannabidiol in the area of cancer-induced peripheral neuropathic pain, and combination therapeutics and methods for the treatment of neurodegenerative diseases.
Dr. Josep Bassaganya-Riera
CHAIRMAN, PRESIDENT AND CEO, LANDOS BIOPHARMA
Landos Biopharma is rapidly developing into an integrated biotech company with a powerful R&D engine and a robust commercial arm.
Scott Bluestein
CEO & CIO, HERCULES CAPITAL
Hercules Capital explains why it is well positioned to benefit from a thriving life sciences and technology scene.
James Sapirstein
PRESIDENT & CEO, AZURRX BIOPHARMA
AzurRx Biopharma has benefitted from the availability of financing to expand its pipeline.
William H. Lewis
CHAIR & CEO, INSMED
2020 has been a transformative year for Insmed that is now undertaking three exciting programs for rare and serious diseases.
Christiana Bardon
PORTFOLIO MANAGER, BURRAGE CAPITAL, MANAGING DIRECTOR, ONCOLOGY IMPACT FUND, MPM CAPITAL
Burrage Capital speaks to GBR about the current wave of enthusiasm investors are showing towards biotech.
Jay A. Roberts
PRESIDENT & CEO, CANCER GENETICS, INC.
Cancer Genetics has merged with StemoniX and is addressing the challenges of drug discovery using innovative, science-based technologies and a highly-developed focus on the regulatory community.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Mexico Chemicals 2024
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
